Hong Kong Stock Connect | Fuhong Hanlin (02696) rose nearly 7% in early trading. Core products saw increased volume and overseas revenue grew significantly. Annual product revenue exceeded 5.8 billion yuan.

LootboxPhobia · 2026-03-27T03:03:38+00:00

Fuhong Hanlin's stock price rose nearly 7% in the early trading session, announcing progress in the clinical research of HLX701 combined therapy for advanced colorectal cancer, and receiving approval from Health Canada for two drugs. Revenue is expected to grow by 16.5% year-on-year in 2025, with a net profit of 827 million yuan, and overseas revenue is rapidly increasing.

LootboxPhobia

2026-03-27 03:03:38

Abstract generation in progress

Info from Tonghuashun Finance APP: Fuluhong Hanshin (02696) rose nearly 7% in early trading. As of press time, it was up 6.21%, trading at HKD 70.1, with a turnover of HKD 12.1671 million.

On the news front, Fuluhong Hanshin announced that the first patient dose of HLX701 (recombinant human SIRPα-IgG4 Fc fusion protein injection) combined with cetuximab and chemotherapy for advanced colorectal cancer in Phase 1b/2 clinical trials has been completed in mainland China (excluding Hong Kong, Macau, and Taiwan). Additionally, Fuluhong Hanshin’s BILDYOS (dostarlimab) and TUZEMTY (tucatinib) recently received approval for market listing from Health Canada.

Notably, Fuluhong Hanshin’s revenue in 2025 increased by 16.5% year-on-year to HKD 6.67 billion, with net profit attributable to shareholders of HKD 827 million. Shenwan Hongyuan released a research report stating that, benefiting from the sales growth of core products such as Hanquyou and Hanshuang, as well as rapid overseas revenue growth, the company’s global product revenue in 2025 is expected to reach HKD 5.82 billion (up 17.8% YoY). Among them, the global revenue of Hanquyou and Hanshuang was HKD 2.99 billion (up 6.5% YoY) and HKD 1.50 billion (up 14.0% YoY), respectively. Additionally, the company’s overseas product revenue exceeded HKD 200 million (more than 100% YoY increase).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.